ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, has announced that it will expand its footprint in Asia-Pacific with the opening of an office in Manila, Philippines. This announcement follows the recent expansion of ICON’s operations in Seoul, Korea and ICON Central Laboratories’ move to a larger laboratory facility in Singapore.
“With over 800 employees in 14 Asia-Pac countries and 13 years of successful operations in the region, Asia-Pacific is a key market for ICON,” commented Peter Gray, CEO at ICON. “Philippines’ large population, coupled with the country’s well-established network of hospitals, physicians and investigators has made it an attractive location for our clients, and one which we have supported for a number of years through home-based employees. Investing in local support and infrastructure through the office in Manila will ensure that we can support future client demand as they increasingly look to include Asia in their drug development programs.”
ICON has conducted a wide range of clinical studies across all therapeutic areas in Asia-Pacific, and has particular expertise in managing oncology, cardiovascular, CNS and metabolic disorder trials in the region. Current studies range from small local trials to pan-Asia-Pacific and large global programs and are supported by two fully-owned ICON central laboratories, strategically located in Singapore and Bangalore, India. ICON has a presence in 14 countries within the region – Australia, China, Hong Kong, India, Indonesia, Japan, Korea, Malaysia, New Zealand, Philippines, Singapore, Taiwan, Thailand and Vietnam.